Nautilus Neurosciences (Bridgewater, NJ) near commercial-stage specialty neurology pharma focused on migraine and acute pain, closed a $14.5M Series A financing. Participants include Tailwind Capital.
_________________________________________________________________________

NOTE: New OnBioVC Friday feature coming, well…this Friday!

NABsys (Providence, RI) a development-stage company focused on polymerase-free solid-state electronic detection DNA sequencing free of amplification or labeling focused point-of-care clinical use, closed a $7M Series B financing. Participants include Stata Venture Partners and Point Judith Capital. _________________________________________________________________________

NOTE: New OnBioVC Friday feature coming, well…this Friday!

Eleven Biotherapeutics (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on protein therapeutics for the treatment of inflammation and coagulation disorders, closed a $35M Series A financing. Participants include Flagship Ventures and Third Rock Ventures.

_________________________________________________________________________

NOTE: New OnBioVC Friday feature coming, well…this Friday!

Pulmonx (Redwood City, CA) a commercial-stage medical device company focused on minimally invasive devices for the diagnosis and treatment of COPD and other pulmonary disorders, closed a $32M Series C financing. Participants include HealthCap, Kleiner Perkins Caufield & Byers, De Novo Ventures, Latterell Venture Partners, MedVenture Associates, Montreux Equity Partners and Posco BioVentures.

Seahorse Bioscience (Billerica, MA) commercial-stage providers of instruments for cellular bioenergetic measurements for better understanding of the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity, closed a $5M Series D financing. Participants include Commonwealth Capital Ventures, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science Ventures and HLM Venture Partners.

Pearl Therapeutics (Redwood City, CA) a clinical-stage pharma company focused on metered dose inhaler products for the treatment of COPD and asthma, closed a $15M Series C financing. Participants include Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

Merus (Netherlands) a preclinical-stage biopharmaceutical focused on antibody product candidates against targets in oncology, inflammation and infectious disease, closed a $30.7M Series B financing. Participants include Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners and Aglaia Biomedical Ventures.

Kolltan Pharmaceuticals (New Haven, CT) a development-stage biopharmaceutical company focused on monoclonal antibody oncology therapeutics, closed a $8.5M Series B financing. Participants include Celtic Therapeutics Holdings and Tichenor Ventures.

ImpactRx (Mt. Laurel, NJ) a commercial-stage provider of online content measuring the impact of pharmaceutical promotion on the prescribing behavior of the nation’s highest value physicians, closed a $1.2M Series E financing. Participants have included Mediphase Venture Partners, 3i Group, Oxford Bioscience Partners and Merck.

MicroCHIPS (Bedford, MA) a development-stage medical device company focused on implantable drug delivery and biosensing for diabetes and osteoporosis, closed a $16.5M Series C financing. Participants include InterWest Partners, Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital.